← Career intelligence
Free · no sign-up · 3,138 priced deals

The deal tape

A precedent transactions set answers one question: what did somebody actually pay for a company like this one. Every row here is a US public target that filed a merger proxy or a going-private statement since 2020, with the offer per share, the premium to the unaffected price and the enterprise value multiples read from the filing itself rather than bought from a feed. Choose a sector, an industry code and a size band, and the quartiles above the list are the answer for that cut.

What it is not. Private-company deals, non-US targets and any transaction where no proxy was required leave nothing to read, so none of them are here. Neither are minority stakes or asset sales. Where a cross-check failed, the row still appears and says why, and it is held out of every median and quartile so one bad reading cannot move a number you would quote.

What this cut was bought at

Each measure counts the readings that survive its own cross-checks. Fewer than 4 is a coincidence, not a market.

MeasureDeals25thMedian75th
EV / LTM EBITDA2516.0x21.7x36.8x
EV / LTM revenue502.0x3.6x6.4x
Premium to unaffected price5723%35%54%
Premium to 30-day VWAP822%38%44%

Read the EBITDA multiple against the revenue multiple before you use either. Where they disagree sharply the target was priced on growth rather than earnings, and the EBITDA line is the one that will not survive a second question.

Deals by year of announcement
06122010: 8 deals, 1 clean on every measure201082011: 6 deals, 4 clean on every measure201162012: 3 deals, 2 clean on every measure201232013: 4 deals, 3 clean on every measure201342014: 8 deals, 5 clean on every measure201482015: 5 deals, 2 clean on every measure201552016: 7 deals, 4 clean on every measure201672017: 7 deals, 6 clean on every measure201772018: 6 deals, 5 clean on every measure201862019: 2 deals, 2 clean on every measure201922020: 4 deals, 4 clean on every measure202042021: 10 deals, 5 clean on every measure2021102022: 4 deals, 2 clean on every measure202242023: 1 deals, 1 clean on every measure202312024: 5 deals, 5 clean on every measure202452025: 12 deals, 8 clean on every measure2025122026: 5 deals, 2 clean on every measure20265
Clean on every measure In doubt on one measure or both
Median EV / LTM EBITDA by sector
Healthcare: 25.3x median across 14 dealsHealthcare25.3xn=14Industrials: 18.6x median across 10 dealsIndustrials18.6xn=10
Deals by sector
Healthcare: 65 dealsHealthcare65Industrials: 29 dealsIndustrials29Technology: 3 dealsTechnology3
Deals by buyer type
Financial sponsor: 6 dealsFinancial sponsor6Strategic: 97 dealsStrategic97Management / founder: 0 dealsManagement / founder0Controlling holder: 1 dealsControlling holder1Acquisition vehicle: 0 dealsAcquisition vehicle0Unclassified: 43 dealsUnclassified43
Deals by enterprise value
Under $250m: 35 dealsUnder $250m35$250m to $1bn: 28 deals$250m to $1bn28$1bn to $5bn: 21 deals$1bn to $5bn21$5bn to $20bn: 13 deals$5bn to $20bn13Over $20bn: 0 dealsOver $20bn0Not computed: 0 dealsNot computed0
Deals by industry code
Business Services & Software: 229 dealsBusiness Services & Sof…229Depository Institutions: 208 dealsDepository Institutions208Chemicals, Pharmaceuticals & Allied Products: 176 dealsChemicals, Pharmaceutic…176Electronics & Electrical Equipment: 129 dealsElectronics & Electrica…129Instruments, Medical Devices & Optical Goods: 97 dealsInstruments, Medical De…97Holding & Other Investment Offices: 82 dealsHolding & Other Investm…82Oil & Gas Extraction: 76 dealsOil & Gas Extraction76Industrial Machinery & Computers: 66 dealsIndustrial Machinery & …66Electric, Gas & Sanitary Services: 66 dealsElectric, Gas & Sanitar…66Communications: 64 dealsCommunications64
TargetAcquirerIndustryEVEV / EBITDAEV / revenuePremiumFiling
Exactech Inc
2017-10-22 · Public merger · $49.25 a share
Osteon Holdings, L.P.
Strategic
Healthcare$695m25.3x2.6x
54%
DEFM14A
All cash
Exactech Inc
2017-10-22 · Take-private · $49.25 a share
Osteon Holdings, L.P.
Strategic
Healthcare$695m25.3x2.6x
54%
SC 13E3
All cash
NxStage Medical, Inc.
2017-08-07 · Public merger · $30.00 a share
Fresenius Medical Care Holdings, Inc.
Strategic
Healthcare$1.9bn68.5xn.a.
30%
DEFM14A
All cash
Bard C R Inc /Nj/
2017-04-23 · Public merger · $222.93 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Lambda Corp.
Strategic
Healthcare$17bnn.a.4.5x
25%
DEFM14A
Includes stock
Mocon Inc
2017-04-16 · Public merger · $30.00 a share
AMETEK, Inc.
Strategic
Industrials$165m18.5x2.6x
39%
46% to VWAP
DEFM14A
All cash
Ixia
2017-01-30 · Public merger · $19.65 a share
Keysight Technologies, Inc.
Strategic
Industrials$1.5bn42.1x3.2x
45%
DEFM14A
All cash
Vascular Solutions LLC
2016-12-01 · Public merger · $56.00 a share
Teleflex Incorporated
Strategic
Healthcare$943m51.5x5.9x
n.a.
DEFM14A
All cash
Precipio, Inc.
2016-10-12 · Public merger · $0.93 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Transgenomic, Inc.
Strategic
Industrials$30mn.a.n.a.
n.a.
DEFM14A
Includes stock
Cepheid
2016-09-02 · Public merger · $53.00 a share
Danaher Corporation
Strategic
Industrials$3.8bnn.a.6.7x
55%
DEFM14A
All cash
American Science & Engineering, Inc.
2016-06-20 · Public merger · $37.00 a share
OSI Systems, Inc.
Strategic
Healthcare$179mn.a.1.7x
14%
DEFM14A
All cash
St Jude Medical, LLC
2016-04-27 · Public merger · $46.75 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Abbott Laboratories
Strategic
Healthcare$19bn16.5x3.4x
n.a.
DEFM14A
Includes stock
Newport Corp
2016-02-22 · Public merger · $23.00 a share
MKS Instruments, Inc.
Strategic
Industrials$924m12.2x1.5x
50%
DEFM14A
All cash
Cascade Microtech Inc
2016-02-03 · Public merger · $16.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
FormFactor, Inc.
Strategic
Industrials$211m10.0x1.5x
n.a.
DEFM14A
Includes stock
Kla Corp
2015-10-20 · Public merger · $32.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Lam Research
Strategic
Industrials$5.9bnn.a.2.1x
24%
DEFM14A
Includes stock
Sirona Dental Systems, Inc.
2015-09-15 · Public merger · $97.28 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
DENTSPLY International Inc.
Strategic
Healthcare$5.1bn15.8x4.4x
n.a.
DEFM14A
Includes stock
Thoratec Corp
2015-07-21 · Public merger · $63.50 a share
St. Jude Medical
Strategic
Healthcare$3.2bn45.6x6.5x
35%
DEFM14A
All cash
Unilens Vision Inc
2015-07-10 · Public merger · $12.75 a share
Valeant Pharmaceuticals International
Strategic
Healthcare$22m11.2x2.5x
24%
DEFM14A
All cash
Wright Medical Group Inc
2015-05-12 (filed) · Public merger · $27.72 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Tornier N.V.
Strategic
Healthcare$1.5bnn.a.n.a.
28%
DEFM14A
Includes stock
Uroplasty Inc
2014-12-21 · Public merger · $0.78 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Vision-Sciences, Inc.
Strategic
Healthcare$8mn.a.0.3x
56%
DEFM14A
Includes stock
CAREFUSION Corp
2014-10-05 · Public merger · $49.00 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Griffin Sub
Strategic
Healthcare$10bn12.2x2.8x
26%
DEFM14A
Includes stock
Symmetry Medical Inc.
2014-08-04 · Public merger · $7.50 a share
TecoStar Holdings, Inc.
Strategic
Healthcare$434mn.a.1.1x
n.a.
DEFM14A
All cash
Medical Action Industries Inc
2014-06-24 · Public merger · $13.80 a share
Owens & Minor, Inc.
Strategic
Healthcare$306m36.9x1.1x
n.a.
DEFM14A
All cash
Measurement Specialties Inc
2014-06-18 · Public merger · $86.00 a share
TE Connectivity Ltd.
Strategic
Industrials$1.3bn19.0xn.a.
n.a.
DEFM14A
All cash
LVB Acquisition, Inc.
2014-04-24 · Public merger · $8.41 a share
Held out of the multiples: consideration includes stock: the cash figure is not the price
Zimmer Holdings, Inc.
Strategic
Healthcare$10bn17.7x3.3x
n.a.
DEFM14A
Includes stock
Zygo Corp
2014-04-10 · Public merger · $19.25 a share
AMETEK, Inc.
Strategic
Industrials$267m11.3x1.6x
31%
DEFM14A
All cash

How to use a set like this

Cut to the narrowest set that still holds eight or ten deals, then quote the range rather than the median. An interviewer who asks where software takes out will accept a spread and press on a single number, because the single number implies a precision the set does not have. Say which deals sit at each end and why: the top of a range is usually a contested auction or a strategic buyer with synergies, the bottom a controlling holder buying in the minority.

Premiums move with the reference price, not only with the deal. A bidder quotes the period that flatters the offer, so read the premium to the unaffected close beside the premium to the thirty-day average and notice when they diverge.

What each column means

Enterprise value.
Offer per share times shares outstanding, plus net debt at the last balance sheet before the merger agreement. It is blank where either piece was missing, and those rows are in the “not computed” band rather than in a size they never earned.
Premium.
The offer against the unaffected price, which is the last close before the deal became known. Where the filing states a premium to the thirty-day volume-weighted average, that is shown next to it.
Deal type.
A take-private is bought by an affiliate, which is what triggers the Schedule 13E-3 and the fuller disclosure that comes with it. A public merger is an arm’s-length buyer, disclosed through the merger proxy.
In doubt.
A cross-check the reading could not satisfy: an equity value far from the fee-table figure, a multiple outside any sane band, or consideration that is partly stock so the per-share cash figure is not the price. The row stays visible, and it is set aside only for the measures the doubt reaches. A cash-and-stock deal cannot price a multiple and still states a premium the filing itself computed, so it counts in one and not the other.

Company names, tickers and logos are the trademarks of their respective owners and appear here to identify the company whose public figures are being used. L3VLUP is not affiliated with, sponsored by or endorsed by any company shown, and nothing here is a statement by or about that company. More